Novigenix And BioLizard Partner To Deliver Early Cancer Detection With AI Augmented Liquid Biopsy

Pixabay License | Source:  Pete Linforth , no changes made.

Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, has formed a collaboration agreement with BioLizard, an innovative bioinformatics company that aims to solve the most challenging questions in biology.

Founded in 2014, based in Épalinges, District de Lausanne, Switzerland, Novigenix is committed to providing a new understanding of the human host response against cancer. The Company’s founding vision was that Immuno-Transcriptomics will bring unprecedented advances in diagnosing and treating cancer patients leading to significant improvement in healthcare. Novigenix’s unique Immuno-Transcriptomics technology enables an accelerated identification of disease specific mRNA signatures of circulating immune cells, which combined with machine learning and predictive algorithms, can predict onset and progression of disease. The Company has established a valuable multicultural biobank and database of over 1,400 patients at risk of colorectal cancer (CRC) and has launched its first blood-based molecular diagnostic product, Colox®, for the early detection of colon cancer.

BioLizard NV is an early stage bioinformatics company based out of Ghent, Belgium with offices in Amsterdam, the Netherlands, that aims to solve the most challenging questions in biology and to deliver the answers to the scientific questions of clients utilizing the expertise in bioinformatics, biostatistics, machine learning, artificial intelligence (AI) and data mining. By combining the expertise from diverse backgrounds, BioLizard provides a complete solution to the client – from data analysis to the system integration and the development of an AI-aided interpretation system and so on.

Featured Partners

Under the terms of the agreement, BioLizard will develop an AI-based bioinformatics algorithm to support the transition of the company’s first Immuno-Transcriptomic RT-PCR based product for early colon cancer detection Colox® onto Novigenix’s LITOseek™ platform (blood Immuno-Transcriptomic sequence platform with machine learning) as well as other new products under development.

“We’re proud to collaborate with Novigenix, one of the leading Immuno-transcriptomic companies, which is developing innovative tests for early cancer detection and therapy monitoring.” … “We will use our extensive expertise in bioinformatics, machine learning, artificial intelligence and data mining to co-develop a unique proprietary clinical diagnostic algorithm for Novigenix LITOseek platform.” – Dr. Gerben Menschaert, co-founder, BioLizard

“Partnering with BioLizard helps us to fast track the development of our LITOseek platform.” … “Our current Colox customers will strongly benefit from this new development once we launch our new colon cancer test on the LITOseek platform, but it will also fast track the progress of new products that are currently in the pipeline.” – Dr. Jan Groen, CEO, Novigenix

Sources

  1. https://www.businesswire.com/news/home/20190918005853/en/Novigenix-BioLizard-Sign-Collaboration-Agreement-Development-NGS
  2. https://www.crunchbase.com/organization/novigenix#section-overview
  3. https://www.linkedin.com/company/biolizard/about/
advertisement